Halozyme Therapeutics Inc (HALO)

48.13 +0.10 (+0.21%) USD  |  NASDAQ  |  Dec 27, 16:00
48.19 +0.06 (+0.12%) After-Hours: 20:00
More

Halozyme Therapeutics Research and Development Expense (Annual): 76.36M for Dec. 31, 2023

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for HALO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Amicus Therapeutics Inc 152.38M
Lexicon Pharmaceuticals Inc 58.89M
Novavax Inc 737.50M
Kura Oncology Inc 115.24M
TransMedics Group Inc 63.27M